Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.
renal cancer
therapeutic drug monitoring
tyrosine kinase inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jan 2023
03 Jan 2023
Historique:
received:
01
12
2022
revised:
28
12
2022
accepted:
30
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
9
1
2023
Statut:
epublish
Résumé
Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale to develop therapeutic drug monitoring for these drugs. General considerations of such monitoring of the several groups of anticancer drugs are given, with a focus on oral therapy. Pharmacokinetics and the factors of inter- and intraindividual variabilities of these tyrosine kinase inhibitors are described together with an exhaustive presentation of their pharmacokinetic/pharmacodynamic relationships. The latter was observed in studies where every patient was treated with the same dose, and the results of several prospective studies based on dose individualization support the practice of increasing individual dosage in case of low observed plasma drug concentrations. Finally, the benefits and limits of therapeutic drug monitoring as a routine practice are discussed.
Identifiants
pubmed: 36612311
pii: cancers15010313
doi: 10.3390/cancers15010313
pmc: PMC9818258
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Clin Cancer Res. 2016 Dec 1;22(23):5738-5746
pubmed: 27470967
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Med Oncol. 2018 Mar 9;35(4):51
pubmed: 29524031
Pharmaceuticals (Basel). 2021 Sep 15;14(9):
pubmed: 34577627
Clin Cancer Res. 2017 Jan 15;23(2):330-335
pubmed: 27793960
Pharmaceuticals (Basel). 2021 May 24;14(6):
pubmed: 34073681
Clin Pharmacokinet. 2019 May;58(5):651-658
pubmed: 30367352
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Clin Genitourin Cancer. 2019 Apr;17(2):e306-e313
pubmed: 30598361
Clin Cancer Res. 2009 Jun 15;15(12):4220-7
pubmed: 19509175
Invest New Drugs. 2012 Oct;30(5):2066-79
pubmed: 22327313
Invest New Drugs. 2021 Apr;39(2):595-604
pubmed: 33098047
Invest New Drugs. 2012 Oct;30(5):1991-2000
pubmed: 22006162
Clin Pharmacokinet. 2014 Apr;53(4):305-25
pubmed: 24566736
Eur J Cancer. 2021 Nov;157:428-440
pubmed: 34597977
Clin Cancer Res. 2019 Mar 1;25(5):1479-1485
pubmed: 30765389
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
Curr Oncol Rep. 2018 Jun 21;20(8):65
pubmed: 29931399
PLoS One. 2012;7(5):e37563
pubmed: 22666367
Clin Cancer Res. 2007 Mar 1;13(5):1367-73
pubmed: 17332278
Eur J Clin Pharmacol. 2020 Apr;76(4):579-587
pubmed: 31932871
Br J Clin Pharmacol. 2011 Aug;72(2):294-305
pubmed: 21392074
Cancer Chemother Pharmacol. 2018 Jun;81(6):1061-1070
pubmed: 29667066
Pharmacol Res Perspect. 2021 Oct;9(5):e00856
pubmed: 34478238
Br J Cancer. 2014 May 13;110(10):2441-9
pubmed: 24736581
Pharm Res. 2021 Mar;38(3):415-428
pubmed: 33686560
Clin Pharmacokinet. 2020 Jul;59(7):941-948
pubmed: 32020530
Ann Oncol. 2022 Oct;33(10):1071-1082
pubmed: 35777707
Clin Cancer Res. 2012 Apr 1;18(7):2099-107
pubmed: 22307138
Cancer Chemother Pharmacol. 2014 Jun;73(6):1189-96
pubmed: 24705975
Cancer Treat Rev. 2020 Mar;84:101966
pubmed: 32044644
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Eur J Cancer. 2014 Aug;50(12):2040-9
pubmed: 24880774
Clin Cancer Res. 2018 Jul 1;24(13):3005-3013
pubmed: 29330204
Eur J Cancer. 2022 Dec;177:63-71
pubmed: 36327527
Lancet Oncol. 2020 May;21(5):e265-e279
pubmed: 32359502
Invest New Drugs. 2012 Oct;30(5):2046-9
pubmed: 22038662
J Clin Pharmacol. 2013 May;53(5):491-504
pubmed: 23553560
Pharmacol Res Perspect. 2021 Apr;9(2):e00757
pubmed: 33745217
Clin Pharmacokinet. 2014 Feb;53(2):185-96
pubmed: 24135988
Clin Genitourin Cancer. 2022 Aug;20(4):390.e1-390.e8
pubmed: 35428585
Drug Metab Pharmacokinet. 2012;27(6):631-9
pubmed: 22673043
Int J Cancer. 2022 Jan 15;150(2):308-316
pubmed: 34494665
Clin Pharmacol Ther. 2014 Apr;95(4):359-61
pubmed: 24646485
PLoS One. 2012;7(8):e42875
pubmed: 22912756
J Clin Oncol. 2020 Nov 1;38(31):3672-3684
pubmed: 32915679
Clin Genitourin Cancer. 2015 Aug;13(4):350-358
pubmed: 25701374
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1208-1220
pubmed: 34342170
Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
pubmed: 19967539
Clin Pharmacokinet. 2017 Mar;56(3):293-303
pubmed: 27534647
Clin Cancer Res. 2016 May 1;22(9):2127-32
pubmed: 26581244
Clin Cancer Res. 2003 Jan;9(1):327-37
pubmed: 12538485
Cancer Chemother Pharmacol. 2017 Dec;80(6):1171-1178
pubmed: 29051995
Cancers (Basel). 2022 Aug 03;14(15):
pubmed: 35954446
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Invest New Drugs. 2015 Feb;33(1):257-68
pubmed: 25344452
Cancer Chemother Pharmacol. 2017 Aug;80(2):385-393
pubmed: 28667354
Cancer Chemother Pharmacol. 2014 Dec;74(6):1307-19
pubmed: 25297989
Br J Cancer. 2014 Nov 11;111(10):1909-16
pubmed: 25349968
Fundam Clin Pharmacol. 2018 Feb;32(1):98-107
pubmed: 29055166
Int J Clin Oncol. 2018 Oct;23(5):936-943
pubmed: 29860539
Eur J Cancer. 2014 Aug;50(12):2020-36
pubmed: 24928190
Clin Cancer Res. 2016 Dec 1;22(23):5626-5628
pubmed: 27663599
BMC Cancer. 2022 Mar 2;22(1):228
pubmed: 35236333
J Clin Oncol. 2010 May 10;28(14):2381-8
pubmed: 20385986
ESMO Open. 2021 Dec;6(6):100312
pubmed: 34864351
J Clin Oncol. 2006 Jan 1;24(1):25-35
pubmed: 16314617